Sara Sakowitz MPH , Syed Shahyan Bakhtiyar MD , Saad Mallick MD , Sara Pereira MD , Jennifer S. Nelson MD , Rushi Parikh MD , Robert S.D. Higgins MD, MSHA , Richard J. Shemin MD , Peyman Benharash MD
{"title":"Insurance-Based Disparities in Cardiac Allograft Vasculopathy After Heart Transplantation Are Mediated by Care at High-Volume Centers","authors":"Sara Sakowitz MPH , Syed Shahyan Bakhtiyar MD , Saad Mallick MD , Sara Pereira MD , Jennifer S. Nelson MD , Rushi Parikh MD , Robert S.D. Higgins MD, MSHA , Richard J. Shemin MD , Peyman Benharash MD","doi":"10.1016/j.athoracsur.2025.01.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Socioeconomic disadvantage and Medicaid insurance have been linked with inferior survival after heart transplantation, yet the contributing mechanisms remain to be elucidated. We evaluated the association of Medicaid with the development of cardiac allograft vasculopathy (CAV).</div></div><div><h3>Methods</h3><div>We considered heart transplant recipients aged ≥18 years within the 2004-2022 Organ Procurement and Transplantation Network. CAV was defined as any evidence of angiographic coronary disease. Institutional volume was computed, with hospitals in the highest quartile (≥19 cases/y) categorized as high-volume centers. Patients were stratified by insurance into the Medicaid and Non-Medicaid cohorts. The study period was divided into the pre-Affordable Care Act (ACA; 2004-2013) and post-ACA eras (2014-2022).</div></div><div><h3>Results</h3><div>Of 37,073 heart transplant recipients, 4875 (13%) were insured by Medicaid. The overall incidence of CAV was 31%. After risk-adjustment, Medicaid insurance was linked with significantly greater likelihood of developing CAV over 5 years (Hazard Ratio [HR], 1.08, 95% CI, 1.01-1.16). Importantly, this effect seems to have emerged in the post-ACA era (Pre-ACA HR, 1.07, 95% CI 0.84-1.36; Post-ACA HR, 1.11, 95% CI, 1.02-1.21). Furthermore, among patients at high-volume centers, Medicaid insurance was linked with similar CAV likelihood (HR, 1.04, 95% CI, 0.95-1.14). Yet, considering those treated at non-high-volume centers, Medicaid was associated with significantly greater CAV hazard (HR, 1.14, 95% CI, 1.03-1.26). Overall, Medicaid remained associated with inferior patient (HR, 1.31, 95% CI, 1.21-1.42) and allograft survival at 5 years (HR, 1.29, 95% CI, 1.19-1.39).</div></div><div><h3>Conclusions</h3><div>Medicaid-insured recipients faced inferior survival and greater risk of CAV over 5 years. Our work encourages closer follow-up and treatment for vulnerable populations in the months and years post-transplantation.</div></div>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":"120 3","pages":"Pages 551-560"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003497525000724","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Socioeconomic disadvantage and Medicaid insurance have been linked with inferior survival after heart transplantation, yet the contributing mechanisms remain to be elucidated. We evaluated the association of Medicaid with the development of cardiac allograft vasculopathy (CAV).
Methods
We considered heart transplant recipients aged ≥18 years within the 2004-2022 Organ Procurement and Transplantation Network. CAV was defined as any evidence of angiographic coronary disease. Institutional volume was computed, with hospitals in the highest quartile (≥19 cases/y) categorized as high-volume centers. Patients were stratified by insurance into the Medicaid and Non-Medicaid cohorts. The study period was divided into the pre-Affordable Care Act (ACA; 2004-2013) and post-ACA eras (2014-2022).
Results
Of 37,073 heart transplant recipients, 4875 (13%) were insured by Medicaid. The overall incidence of CAV was 31%. After risk-adjustment, Medicaid insurance was linked with significantly greater likelihood of developing CAV over 5 years (Hazard Ratio [HR], 1.08, 95% CI, 1.01-1.16). Importantly, this effect seems to have emerged in the post-ACA era (Pre-ACA HR, 1.07, 95% CI 0.84-1.36; Post-ACA HR, 1.11, 95% CI, 1.02-1.21). Furthermore, among patients at high-volume centers, Medicaid insurance was linked with similar CAV likelihood (HR, 1.04, 95% CI, 0.95-1.14). Yet, considering those treated at non-high-volume centers, Medicaid was associated with significantly greater CAV hazard (HR, 1.14, 95% CI, 1.03-1.26). Overall, Medicaid remained associated with inferior patient (HR, 1.31, 95% CI, 1.21-1.42) and allograft survival at 5 years (HR, 1.29, 95% CI, 1.19-1.39).
Conclusions
Medicaid-insured recipients faced inferior survival and greater risk of CAV over 5 years. Our work encourages closer follow-up and treatment for vulnerable populations in the months and years post-transplantation.
背景:社会经济劣势和医疗保险与心脏移植术后生存率较低有关,但其作用机制仍有待阐明。我们评估了医疗补助与心脏移植血管病变(CAV)发展的关系。方法:我们考虑了2004-2022年器官获取和移植网络中年龄≥18岁的心脏移植受者。CAV被定义为任何冠状动脉造影疾病的证据。计算机构数量,最高四分位数(≥19例/年)的医院被归类为高容量中心。根据保险将患者分为医疗补助组和非医疗补助组。研究期间分为前平价医疗法案(ACA);2004-2013年)和后aca时代(2014-2022年)。结果:在37,073名心脏移植受者中,有4,875名(13%)参加了医疗补助计划。CAV的总发病率为31%。风险调整后,医疗补助保险与5年内发生CAV的可能性显著增加相关(风险比[HR] 1.08, 95%可信区间[CI] 1.01-1.16)。重要的是,这种效应似乎在后aca时代出现(Pre-ACA HR 1.07, CI 0.84-1.36;aca后HR 1.11, CI 1.02-1.21)。此外,在高容量中心的患者中,医疗补助保险与类似的CAV可能性相关(HR 1.04, CI 0.95-1.14)。然而,考虑到那些在非高容量中心接受治疗的患者,医疗补助与更大的CAV风险相关(HR 1.14, CI 1.03-1.26)。总体而言,医疗补助仍然与劣势患者(HR 1.31, CI 1.21-1.42)和同种异体移植5年生存率相关(HR 1.29, CI 1.19-1.39)。结论:医疗保险受助人在5年内面临较低的生存率和较高的CAV风险。我们的工作鼓励弱势群体在移植后的几个月和几年里进行更密切的随访和治疗。
期刊介绍:
The mission of The Annals of Thoracic Surgery is to promote scholarship in cardiothoracic surgery patient care, clinical practice, research, education, and policy. As the official journal of two of the largest American associations in its specialty, this leading monthly enjoys outstanding editorial leadership and maintains rigorous selection standards.
The Annals of Thoracic Surgery features:
• Full-length original articles on clinical advances, current surgical methods, and controversial topics and techniques
• New Technology articles
• Case reports
• "How-to-do-it" features
• Reviews of current literature
• Supplements on symposia
• Commentary pieces and correspondence
• CME
• Online-only case reports, "how-to-do-its", and images in cardiothoracic surgery.
An authoritative, clinically oriented, comprehensive resource, The Annals of Thoracic Surgery is committed to providing a place for all thoracic surgeons to relate experiences which will help improve patient care.